France's Ipsen Q1 revenue rises 17%, rare disease sales more than double

Ipsen SA

23/04/2026 06:08

Overview

France biopharma firm's Q1 revenue rose 17% as reported, driven by all therapeutic areas

Rare disease sales more than doubled, led by Iqirvo and Bylvay performance

Company confirmed full-year 2026 guidance for sales growth and operating margin

Outlook

Ipsen confirms 2026 guidance for total sales growth greater than 13% at constant currency

Company expects core operating margin greater than 35% of total sales for 2026

Ipsen anticipates adverse currency impact of around 1% on total sales in 2026

Result Drivers

RARE DISEASE FRANCHISE - Growth in Rare Disease sales, particularly from Iqirvo and Bylvay, contributed significantly to Q1 results, per CEO David Loew

BROAD-BASED SALES GROWTH - All three therapeutic areas contributed to total sales growth, with portfolio momentum accelerating outside Somatuline

Company press release: ID:nGNXbK2HKz

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 1.07 bln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Ipsen SA is €155.00, about 3.2% below its April 22 closing price of €160.10

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)